GT Apeiron Therapeutics
Yanfeng is the CMC director of Apeiron Therapeutics. He has over 15 years of experience in drug discovery and non-clinical development with a focus on CMC. Prior to joining Apeiron, he served as the R&D director at 2Y-Chem Co., LTD., where he made significant contributions and led several programs through the non-clinical development phase and into phase 1 clinical trials. Moreover, Yanfeng has developed and supported several IND and ANDA applications. Yanfeng obtained his master's degree in Pharmaceutical Chemistry from China Pharmaceutical University.
This person is not in any teams
GT Apeiron Therapeutics
Apeiron Therapeutics intends to develop breakthrough investigational medicines by harnessing the power of artificial intelligence which drastically increases efficiency throughout the drug discovery process, from target selection, hit identification, lead optimization to pre-clinical studies and clinical trials.